JPH036149B2 - - Google Patents
Info
- Publication number
- JPH036149B2 JPH036149B2 JP56188511A JP18851181A JPH036149B2 JP H036149 B2 JPH036149 B2 JP H036149B2 JP 56188511 A JP56188511 A JP 56188511A JP 18851181 A JP18851181 A JP 18851181A JP H036149 B2 JPH036149 B2 JP H036149B2
- Authority
- JP
- Japan
- Prior art keywords
- propanone
- thienyl
- phenyl
- compound
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 8
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 5
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 5
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims description 4
- 239000012442 inert solvent Substances 0.000 claims description 4
- -1 alkali metal cation Chemical class 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- HDGBVLOEKJOBRH-UHFFFAOYSA-N 1-[3-[2-hydroxy-3-(propylamino)propoxy]-4-methylthiophen-2-yl]-3-phenylpropan-1-one;hypochlorous acid Chemical compound ClO.CC1=CSC(C(=O)CCC=2C=CC=CC=2)=C1OCC(O)CNCCC HDGBVLOEKJOBRH-UHFFFAOYSA-N 0.000 claims description 2
- PVVSRISLNYSAKL-UHFFFAOYSA-N 1-[3-[2-hydroxy-3-(propylamino)propoxy]-5-methylthiophen-2-yl]-3-phenylpropan-1-one;hypochlorous acid Chemical compound ClO.C1=C(C)SC(C(=O)CCC=2C=CC=CC=2)=C1OCC(O)CNCCC PVVSRISLNYSAKL-UHFFFAOYSA-N 0.000 claims description 2
- UJPYHJRAMUEQKL-UHFFFAOYSA-N 1-[3-[2-hydroxy-3-(propylamino)propoxy]thiophen-2-yl]-3-phenylpropan-1-one;hypochlorous acid Chemical compound ClO.C1=CSC(C(=O)CCC=2C=CC=CC=2)=C1OCC(O)CNCCC UJPYHJRAMUEQKL-UHFFFAOYSA-N 0.000 claims description 2
- QJQCCYRQBPKXSP-UHFFFAOYSA-N 1-[3-[3-(butylamino)-2-hydroxypropoxy]thiophen-2-yl]-3-phenylpropan-1-one;hypochlorous acid Chemical compound ClO.C1=CSC(C(=O)CCC=2C=CC=CC=2)=C1OCC(O)CNCCCC QJQCCYRQBPKXSP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- GJACKNUPVZDHQQ-UHFFFAOYSA-N 1-[3-[2-hydroxy-3-(propylamino)propoxy]-4,5-dimethylthiophen-2-yl]-3-phenylpropan-1-one;hypochlorous acid Chemical compound ClO.CC1=C(C)SC(C(=O)CCC=2C=CC=CC=2)=C1OCC(O)CNCCC GJACKNUPVZDHQQ-UHFFFAOYSA-N 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 230000008018 melting Effects 0.000 description 13
- 238000002844 melting Methods 0.000 description 13
- 206010003119 arrhythmia Diseases 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 230000006793 arrhythmia Effects 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 5
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 5
- 229940039750 aconitine Drugs 0.000 description 5
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 5
- 230000003288 anthiarrhythmic effect Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- RFSKGCVUDQRZSD-UHFFFAOYSA-N 3-methoxythiophene Chemical compound COC=1C=CSC=1 RFSKGCVUDQRZSD-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 3
- 229960000203 propafenone Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000003663 ventricular fibrillation Diseases 0.000 description 3
- NGNQVLBGOQRLFL-UHFFFAOYSA-N 1-[3-(oxiran-2-ylmethoxy)thiophen-2-yl]-3-phenylpropan-1-one Chemical compound S1C=CC(OCC2OC2)=C1C(=O)CCC1=CC=CC=C1 NGNQVLBGOQRLFL-UHFFFAOYSA-N 0.000 description 2
- LSSMRBBQCHSDNS-UHFFFAOYSA-N 3-methoxythiophene-2-carboxylic acid Chemical compound COC=1C=CSC=1C(O)=O LSSMRBBQCHSDNS-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- LNUUCRULGDJJFI-UHFFFAOYSA-N 1-(3-hydroxy-4,5-dimethylthiophen-2-yl)-3-phenylpropan-1-one Chemical compound CC1=C(C)SC(C(=O)CCC=2C=CC=CC=2)=C1O LNUUCRULGDJJFI-UHFFFAOYSA-N 0.000 description 1
- JAMUQJWODRUNEV-UHFFFAOYSA-N 1-(3-hydroxy-4-methylthiophen-2-yl)-3-phenylpropan-1-one Chemical compound CC1=CSC(C(=O)CCC=2C=CC=CC=2)=C1O JAMUQJWODRUNEV-UHFFFAOYSA-N 0.000 description 1
- QMLTUPMRSDKBDK-UHFFFAOYSA-N 1-(3-hydroxy-5-methylthiophen-2-yl)-3-phenylpropan-1-one Chemical compound S1C(C)=CC(O)=C1C(=O)CCC1=CC=CC=C1 QMLTUPMRSDKBDK-UHFFFAOYSA-N 0.000 description 1
- YWMOXFOYIVUYTD-UHFFFAOYSA-N 1-(3-hydroxythiophen-2-yl)-3-phenylpropan-2-one Chemical compound C1=CSC(CC(=O)CC=2C=CC=CC=2)=C1O YWMOXFOYIVUYTD-UHFFFAOYSA-N 0.000 description 1
- KTIGJGKPBULVFS-UHFFFAOYSA-N 1-[4,5-dimethyl-3-(oxiran-2-ylmethoxy)thiophen-2-yl]-3-phenylpropan-1-one Chemical compound C1OC1COC=1C(C)=C(C)SC=1C(=O)CCC1=CC=CC=C1 KTIGJGKPBULVFS-UHFFFAOYSA-N 0.000 description 1
- JEZAEGDBHVGRKC-UHFFFAOYSA-N 1-[4-methyl-3-(oxiran-2-ylmethoxy)thiophen-2-yl]-3-phenylpropan-1-one Chemical compound C1OC1COC=1C(C)=CSC=1C(=O)CCC1=CC=CC=C1 JEZAEGDBHVGRKC-UHFFFAOYSA-N 0.000 description 1
- XIYYANGEXAUUCT-UHFFFAOYSA-N 1-[5-methyl-3-(oxiran-2-ylmethoxy)thiophen-2-yl]-3-phenylpropan-1-one Chemical compound C=1C=CC=CC=1CCC(=O)C=1SC(C)=CC=1OCC1CO1 XIYYANGEXAUUCT-UHFFFAOYSA-N 0.000 description 1
- VSGMXBVOHKACCP-UHFFFAOYSA-N 2,3,4-trimethoxythiophene Chemical compound COC1=CSC(OC)=C1OC VSGMXBVOHKACCP-UHFFFAOYSA-N 0.000 description 1
- FOTITZRWZUAVPH-UHFFFAOYSA-N 2-phenylpropanoyl chloride Chemical compound ClC(=O)C(C)C1=CC=CC=C1 FOTITZRWZUAVPH-UHFFFAOYSA-N 0.000 description 1
- WSHWKCQZDNZGFV-UHFFFAOYSA-N 3-methoxy-4,5-dimethylthiophene-2-carboxylic acid Chemical compound COC=1C(C)=C(C)SC=1C(O)=O WSHWKCQZDNZGFV-UHFFFAOYSA-N 0.000 description 1
- HGDGACBSGVRCSM-UHFFFAOYSA-N 3-methoxy-4-methylthiophene Chemical compound COC1=CSC=C1C HGDGACBSGVRCSM-UHFFFAOYSA-N 0.000 description 1
- UQXXEJYOFLKCHS-UHFFFAOYSA-N 3-methoxy-4-methylthiophene-2-carboxylic acid Chemical compound COC=1C(C)=CSC=1C(O)=O UQXXEJYOFLKCHS-UHFFFAOYSA-N 0.000 description 1
- IYTOVCKSPJGCOJ-UHFFFAOYSA-N 3-methoxy-5-methylthiophene-2-carboxylic acid Chemical compound COC=1C=C(C)SC=1C(O)=O IYTOVCKSPJGCOJ-UHFFFAOYSA-N 0.000 description 1
- ICQPBAWSBLMHGD-UHFFFAOYSA-N 4-methoxy-2-methylthiophene Chemical compound COC1=CSC(C)=C1 ICQPBAWSBLMHGD-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- SEMVRXMFCHXUMD-UHFFFAOYSA-N methyl 3-hydroxythiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1O SEMVRXMFCHXUMD-UHFFFAOYSA-N 0.000 description 1
- MWADWXJPBMFRGL-UHFFFAOYSA-N methyl 3-methoxythiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1OC MWADWXJPBMFRGL-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001519 thymoleptic effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Description
æ¬çºæã¯ãæ²»ççã«äŸ¡å€ãã掻æ§ãæããäžè¬
åŒ ãåŒäžãåã³R1ã¯ç¬ç«ããŠæ°ŽçŽ åã¯ã¡ãã«
ã§ããããã㊠R2ã¯ïœâãããã«ãïœâããã«ãã€ãœããã«
åã¯ã¿ãŒã·ã€ãªãŒâããã«ã§ããã ã®ïŒâãïŒâïŒïŒâããããã·âïŒâã¢ã«ãã«ã¢ã
ãããããã·ïŒâïŒâããšãã«ãâïŒâããšãã«â
ïŒâããããã³ã®æ°èŠèªå°äœåã³ãããã®é žä»å
å¡©ããããã®è£œé æ¹æ³åã³ãããæå¹æåãšããŠ
å«æããæäžæŽèè¬ã«é¢ããã æ¬çºæã®æ¹æ³ã¯ãäžè¬åŒ ãåŒäžãåã³R1ã¯äžèšã§å®çŸ©ãããŠããåŠ
ãã§ããããã㊠Meã¯ã¢ã«ã«ãªéå±ã®ã«ããªã³ã§ããã ã®ååç©ãåŒ ã®ãšãã¯ãããããªã³ãšåå¿ããããããŠãã®ã
ãã«ããŠåŸãããåŒ ãåŒäžãåã³R1ã¯äžèšã§å®çŸ©ãããŠããåŠ
ãã§ããã ã®ååç©ãäžè¬åŒ R2âNH2 ïŒïŒ ãåŒäžãR2ã¯äžèšã§å®çŸ©ãããŠããåŠãã§ã
ãã ã®ã¢ã«ãã«ã¢ãã³ãšåå¿ããããããŠåžæãããª
ãåŸãããåŒïŒïŒã®å¡©åºãé žä»å å¡©ã«è»¢åãã
ããšãããªã€ãŠããã äžè¬åŒïŒïŒã®æ°èŠååç©ã¯çš®ã ãªåç©ã¢ãã«
ïŒanimal modelsïŒã«å¯ŸããŠäœãæäžéã§ãã§ã«
é¡èãªæäžæŽè掻æ§ãæããããããã¯çµå£æäž
ããæã«ã掻æ§ã§ããã 奜é©ãªçš®é¡ã¯R2ãïœâãããã«ã§ããåŒïŒïŒ
ã®ååç©ã®ãã®ã§ããã ãããã®è£œè¬åŠçæ§è³ªã®ããã«ãæ°èŠååç©å
ã³ãããã®é žä»å å¡©ã¯åç¬ã§åã¯ä»ã®æŽ»æ§ç©è³ªãš
æ··åããŠãå¿æé害ã®æ²»ççšã®æ®éã®è£œå€ã®åœ¢ã§
ïŒåã³é 延圢ã§ïŒäœ¿çšã§ããã æ¬çºæã«åŸãååç©ïŒïŒãšååç©ïŒïŒã®å
å¿ã¯å¥œé©ã«ã¯äžæŽ»æ§æº¶åªäžã§ãç¹ã«å¥œé©ã«ã¯éå°
éã®ãšãã¯ãããããªã³äžã§ã110ã140âã®éã®
枩床ã«ãããŠå®æœãããã äžéçæç©ååç©ïŒïŒãšååç©ïŒïŒã®åå¿
ã¯å¥œé©ã«ã¯äžæŽ»æ§æº¶åªäžã§ãç¹ã«å¥œé©ã«ã¯éå°é
ã®ã¢ãã³ïŒïŒäžã§ã50ã100âã®éã®æž©åºŠã«ã
ããŠå®æœãããã åŒïŒïŒã®ååç©ã®é žä»å å¡©ã¯ããèªäœã¯å ¬ç¥
ã®æ¹æ³ã§ãäŸãã°ã¢ã«ã«ãªåã¯ã€ãªã³äº€æäœãçš
ããŠãéé¢å¡©åºã«è»¢åã§ãããç¡æ©åã¯ææ©é žã
ç¹ã«æ²»çäžæçšãªå¡©ãçæããã®ã«é©ãããã®ã
ãšã®åå¿ã«ããäžèšã®å¡©åºããä»ã®å¡©ãååã§ã
ãã æ°èŠååç©ãšãããã®å¡©ãšã®éã®è¿ãé¢ä¿ã®ã
ãã«ããéé¢å¡©åºããšããè¡šçŸã¯å¯Ÿå¿ããå¡©ãå
æ§ã«ãããŠäžè¬çã«å å«ããŠããã åŒïŒïŒåã³ïŒïŒã®åºçºç©è³ªã¯æç®ããå ¬ç¥
ã§ããã åŒïŒïŒã®ååç©ã¯éé¢ååç©ïŒMeïŒïŒšïŒã
ããæã簡䟿ã«ã¯ã¢ã«ã«ãªæ§æ°Žé žåç©ãã¢ã«ã«ãª
æ§æ°ŽçŽ åç©åã¯ã¢ã«ã«ãªæ§ã¢ã«ã³ã¬ãŒããçšããŠ
補é ã§ããã åŒïŒïŒã®éé¢ååç©ã¯åŒïŒïŒã®å ¬ç¥ã®åå
ç©ããåºçºããŠäžèšã®åå¿åŒã«åŸã補é ã§ããïŒ å®æœäŸ ïŒâãïŒâïŒïŒïŒïŒâãšããã·ããããã·ïŒâ
ïŒâããšãã«ãâïŒâããšãã«âïŒâãããã
ã³ïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒ 1.74ïœïŒ0.076ã¢ã«ïŒã®ãããªãŠã ã50mlã®ç¡
æ°Žã¡ã¿ããŒã«äžã®æº¶è§£ããã17.55ïœïŒ0.076ã¢
ã«ïŒã®ïŒâïŒïŒâããããã·âïŒâããšãã«ïŒœâïŒ
âããšãã«âïŒâããããã³ïŒåŒïŒïŒ²åã³R1
ïŒïŒšïŒMeïŒïŒšïŒãå ãããããŠæº¶æ¶²ãèžçºïŒç
空äžïŒä¹Ÿåºããã50mlã®ãšãã¯ãããããªã³
ïŒïŒãçµæ¶æ§æ®æž£ïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒMe
ïŒNaïŒã«å ãããããŠïŒæééæµããããåå¿
æ··åç©ããã€ããäžã§éããå°éã®ãã³ãŒã³ã§
ãããããããŠæ¶²ãç空äžã§èžçºããããçµæ¶
æ§æ®æž£ãççŽ ãæ·»å ãããŠãã1250mlã®ã·ã¯ãã
ããµã³äžã§å ç±ãããã€ããäžã§éãããããŠ
液ãç空äžã§èžçºããããçµæ¶æ§æ®æž£ã®ééã¯
16.9ïœïŒ77.6ïŒ ïŒã§ãã€ããçæç©ã¯ãã®åŸäœ¿çš
ããã®ã«å åãªã»ã©ã®çŽåºŠã§ãã€ããèç¹ïŒã·ã¯
ããããµã³ïŒ59ã61âã åæ§ã«ããŠäžèšã®ååç©ã補é ã§ããã ïŒâãïŒâïŒïŒïŒïŒâãšããã·ããããã·ïŒâïŒ
âã¡ãã«âïŒâããšãã«ãâïŒâããšãã«âïŒâ
ããããã³ïŒåŒïŒïŒ²ïŒCH3ïŒR1ïŒïŒšïŒãæ²¹ãå
é¢ãããïŒïŒâãïŒâïŒïŒïŒïŒâãšããã·ãããã
ã·ïŒâïŒâã¡ãã«âïŒâããšãã«ãâïŒâããšãã«
âïŒâããããã³ïŒåŒïŒïŒ²ïŒïŒšïŒR1ïŒCH3ïŒã
æ²¹ãåé¢ãããïŒïŒâãïŒïŒïŒâãžã¡ãã«âïŒâ
ïŒïŒïŒïŒâãšããã·ããããã·ïŒâïŒâããšãã«ã
âïŒâããšãã«âïŒâããããã³ïŒåŒïŒïŒ²åã³
R1AïŒCH3ïŒãæ²¹ãåé¢ããããn20 DïŒ1.5535ã ïŒâãïŒâïŒïŒâããããã·âïŒâïœâãããã«
ã¢ããããããã·ïŒâïŒâããšãã«ãâïŒâããšã
ã«âïŒâããããã³âã¯ããããã¬ãŒãïŒåŒïŒ
HClïŒïŒ²åã³R1ïŒïŒšïŒR2ïŒïœâãããã«ïŒ 14.4ïœïŒ0.05ã¢ã«ïŒã®ç²ïŒâãïŒâïŒïŒïŒïŒâãš
ããã·ããããã·ïŒâïŒâããšãã«ãâïŒâããšã
ã«âïŒâããããã³ïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒã
40mlã®ïœâãããã«ã¢ãã³ïŒåŒïŒR2ïŒããã
ã«ïŒäžã§æ¹æããªããïŒæéã«ããã€ãŠéæµãã
ããåå¿æ··åç©ãç空äžã§èžçºãããæ®æž£ã250
mlã®CH2Cl2åã³150mlã®1Nå¡©é žã®éã«åé ããã
çžãåé¢ããæ°ŽçžãïŒÃ50mlã®CH2Cl2ã§æœåºãã
äžç·ã«ããææ©çžã也ç¥ãïŒNa2SO4ïŒããããŠ
ç空äžã§èžçºããããçµæ¶åœ¢ã§åŸãããç²çæç©
ãççŽ ã§å«ãã§ããã¢ã»ãã³ïŒã¡ã¿ããŒã«ïŒïŒïŒ
ïŒçŽ120mlïŒããåçµæ¶åãããããšãã§ãããå
éã12.2ïœïŒ64ïŒ ïŒã®ç¡è²ã®çµæ¶ãèç¹150ã152
âã åæ§ãªæ¹æ³ã§äžèšã®ååç©ãåŸãããïŒ ïŒâãïŒâïŒïŒâããããã·âïŒâïœâããã«ã¢
ããããããã·ïŒâïŒâããšãã«ãâïŒâããšãã«
âïŒâããããã³âã¯ããããã¬ãŒãïŒåŒïŒïŒ²
åã³R1ïŒïŒšïŒR2ïŒïœâããã«ïŒãèç¹ïŒã¢ã»ãã³
ããïŒïŒ113ã114âïŒ ïŒâãïŒâïŒïŒâããããã·âïŒâïœâã¿ãŒã·ã€
ãªãŒâããã«ã¢ããããããã·ïŒâïŒâããšãã«ã
âïŒâããšãã«âïŒâããããã³âã¯ããããã¬
ãŒãïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒR2ïŒã¿ãŒã·ã€ãªãŒ
âããã«ïŒãèç¹ïŒã¢ã»ãã³ããïŒïŒ143ã144âïŒ ïŒâãïŒâã¡ãã«âïŒâïŒïŒâããããã·âïŒâ
ïœâãããã«ã¢ããããããã·ïŒâïŒâããšãã«ã
âïŒâããšãã«âïŒâããããã³âã¯ããããã¬
ãŒãïŒåŒïŒïŒ²ïŒCH3ïŒR1ïŒïŒšïŒR2ïŒïœâãã
ãã«ïŒãèç¹107ã111âïŒã¡ã¿ããŒã«ïŒãšãŒã
ã«ïŒïŒ ïŒâãïŒâã¡ãã«âïŒâïŒïŒâããããã·âïŒâ
ïœâãããã«ã¢ããâããããã·ïŒâïŒâããšã
ã«ãâïŒâããšãã«âïŒâããããã³âã¯ããã
ãã¬ãŒãïŒåŒïŒïŒ²ïŒïŒšïŒR1ïŒCH3ïŒR2ïŒïœâ
ãããã«ïŒãèç¹ïŒ203ã205âïŒã¡ã¿ããŒã«ã
ãïŒïŒïŒâãïŒïŒïŒâãžã¡ãã«âïŒâïŒïŒâããã
ãã·âïŒâïœâãããã«ã¢ããããããã·ïŒâïŒ
âããšãã«ãâïŒâããšãã«âïŒâããããã³â
ã¯ããããã¬ãŒãïŒåŒïŒïŒ²åã³R1ïŒCH3ïŒR2
ïŒïœâãããã«ïŒãèç¹ïŒ126ã128âïŒãã«ãš
ã³ïŒãšãŒãã«ïŒã åºçºååç©ã¯äžèšã®åŠãããŠåŸãããã ïŒâã¡ããã·âããªããšã³âïŒâã«ã«ãã³é ž
ïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒ 13.5ïœïŒ0085ã¢ã«ïŒã®ïŒâããããã·ããªããš
ã³âïŒâã«ã«ãã³é žã¡ãã«ãšã¹ãã«ïŒïŒïŒ²åã³
R1ïŒïŒšïŒã36ïœïŒ0.34ã¢ã«ïŒã®Na2CO3ã®145ml
ã®H2Oäžæº¶æ¶²ã«å ãããããŠæ¹æããªããçæ
é沞ãšããããã次ã«15å以å ã«21.53ïœïŒ0.17
ã¢ã«ïŒã®ç¡«é žãžã¡ãã«ãããã«æ»Žäžãããã®éå
å¿æ··åç©ã®æž©åºŠã¯æ²žç¹ã®ããäžã«ä¿ã€ããæ·»å ã®
å®äºåŸã«ãå ç±ãéæµäžã§20åéç¶ããåå¿æ··å
ç©ãå·åŽããããŠCH2Cl2ã§ïŒãïŒåæœåºããã
äžç·ã«ããææ©çžã2NNaOHã§ïŒåæœåºãã也
ç¥ãïŒNa2SO4ïŒããããŠèžçºããããïŒâã¡ã
ãã·âããªããšã³âïŒâã«ã«ãã³é žã¡ãã«ãšã¹ã
ã«ïŒïŒïŒ²åã³R1ïŒïŒšïŒãããªãæ²¹ç¶æ®æž£ã¯7.1
ïœã®ééãæããŠããããã®æ®æž£ã2.54ïœ
ïŒ0.045ã¢ã«ïŒã®KOHã®70mlã®ã¡ã¿ããŒã«äžæº¶æ¶²
ã®äžã«æº¶è§£ããããããŠ30åééæµãããã次ã«
ã¡ã¿ããŒã«ãç空äžã§èžçé€å»ãããããŠæ®æž£ã
æ°ŽãšCH2Cl2ã®éã«åé ããããæ°Žçžãæ¿HClã§
é žæ§åãããããŠæ²æ®¿ããç¡è²ã®çµæ¶ãå¥ã
ããåéïŒ5.7ïœïŒ54ïŒ ïŒãèç¹180ã183âã åæ§ãªæ¹æ³ã§äžèšã®ååç©ã補é ã§ããïŒ ïŒâã¡ããã·âïŒâã¡ãã«âããªããšã³âïŒâ
ã«ã«ãã³é žïŒåŒïŒïŒ²ïŒCH3ïŒR1ïŒïŒšïŒãèç¹ïŒ
119ã121âïŒ ïŒâã¡ããã·âïŒâã¡ãã«âããªããšã³âïŒâ
ã«ã«ãã³é žïŒåŒïŒïŒ²ïŒïŒšïŒR1ïŒCH3ïŒãèç¹ïŒ
175ã177âïŒ ïŒïŒïŒâãžã¡ãã«âïŒâã¡ããã·âããªããšã³
âïŒâã«ã«ãã³é žïŒåŒïŒïŒ²ïŒR1ïŒCH3ïŒãè
ç¹ïŒ133ã135âã ïŒâã¡ããã·ããªããšã³ïŒïŒïŒ²åã³R1ïŒïŒšïŒ 57ïœã®ïŒâã¡ããã·ããªããšã³âïŒâã«ã«ãã³
é žïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒã15ïœã®Cuâç²æ«ãš
å ±ã«ç åãããããŠåéæ段ãæããèžçã³ã³ã
ã³ãµãšé£çµããŠããèžçãã©ã¹ã³äžã«ç§»ãããè£
眮äžã«65mmHgã®ç空ãé©çšãããããŠèžçãã©
ã¹ã³ã150ã180âã«å ç±ãããèžçããïŒâã¡ã
ãã·ããªããšã³ãåéè£ çœ®äžã«éãããåéïŒ33
ïœïŒ80ïŒ ïŒã åæ§ãªæ¹æ³ã§äžèšã®ååç©ãåŸãããã ïŒâã¡ããã·âïŒâã¡ãã«âããªããšã³ïŒåŒ
ïŒïŒ²ïŒCH3ïŒR1ïŒïŒšïŒã沞ç¹ïŒ83âïŒ30mm
HgïŒ ïŒâã¡ããã·âïŒâã¡ãã«âããªããšã³ïŒåŒ
ïŒïŒ²ïŒïŒšïŒR1ïŒCH3ïŒã沞ç¹ïŒ63ã65âïŒ16ã
ãªããŒã«ïŒ ïŒïŒïŒâãžã¡ããã·âïŒâã¡ããã·âããªããš
ã³ïŒåŒïŒïŒ²åã³R1ïŒCH3ïŒã沞ç¹ïŒ78ã84âïŒ
10mmHgã ïŒâïŒïŒâããããã·âïŒâããšãã«ïŒâïŒâã
ãšãã«âïŒâããããã³ïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒ 44.9ïœïŒ0.266ã¢ã«ïŒã®ããšãã«ããããªã³é ž
ã¯ãã©ã€ãã400mlã®ç¡æ°ŽCHCl3äžã«æº¶è§£ãããã
次ã«50mlã®CHCl3äžã®69.37ïœïŒ0.266ã¢ã«ïŒã®
SnCl4ãããã«æ»Žäžããã次ã«ãæ··åç©ã®æž©åºŠã
15âã«é«ãããããŠ250mlã®CHCl3äžã«æº¶è§£ãã
ãŠãã30.4ïœïŒ0.266ã¢ã«ïŒã®ïŒâã¡ããã·ããª
ããšã³ïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒã30å以å ã«ã
ãã«æ»Žäžãããæ¹æã20åéç¶ãããåå¿æ··åç©
ãäžçšåºŠã®æ¿HClã«æ³šããææ©çžãåé¢ãããã
ãŠCH2Cl2ã§ïŒåæœåºãããäžç·ã«ããææ©çžã
NaHCO3ã®æº¶æ¶²ã§ïŒåæœåºãã也ç¥ã
ïŒNa2SO4ïŒããããŠèžçºããããäž»ãšããŠïŒâ
ïŒïŒâã¡ããã·âïŒâããšãã«ïŒâïŒâããšãã«â
ïŒâããããã³ïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒãããª
ãæ²¹ç¶æ®æž£ïŒ57ïŒ ïŒã270mlã®ããããã³ãŒã³äž
ã«æº¶è§£ããããããŠ62ïœã®ç¡æ°ŽAlCl3ã®270mlã®
ããããã³ãŒã³äžæº¶æ¶²ã«å ãããåå¿æ··åç©ã70
ã90âã§1.5æéæ¹æããå·åŽããæ°·ïŒHClã«æ³š
ãããããŠå®€æž©ã§äžå€æŸçœ®ããã次ã«çžãåé¢
ããæ°ŽçžãCH2Cl2ã§ïŒåæœåºããäžç·ã«ããæ
æ©çžã2NNaOHã§ïŒåæœåºããäžç·ã«ãã
NaOHâçžãæ¿HClã§é žæ§åãããããŠæ²æ®¿ãã
çæç©ãCH2Cl2ã§ïŒåæœåºãããäžç·ã«ãã
CH2Cl2âçžãèžçºãããåŸã«ãæ¿è²ã®çµæ¶æ§æ®
枣ããã³ãŒã³äžã«æº¶è§£ãããã·ãªã«ã²ã«äžã§é
ãããããŠå åæŽæµããã液ã®èžçºåŸã«ã29.1
ïœïŒ47ïŒ ïŒã®çŽç²ãªçæç©ãåŸãããã èç¹ïŒã¡ã¿ããŒã«ïŒïŒ50âã åæ§ãªæ¹æ³ãäžèšã®ååç©ãåŸãããïŒ ïŒâïŒïŒâããããã·âïŒâã¡ãã«âïŒâããš
ãã«ïŒâïŒâããšãã«âïŒâããããã³ïŒåŒã
ïŒCH3ïŒR1ïŒïŒšïŒãèç¹ïŒ36ã38âïŒã¡ã¿ããŒ
ã«ïŒïŒ ïŒâïŒïŒâããããã·âïŒâã¡ãã«âïŒâããš
ãã«ïŒâïŒâããšãã«âïŒâããããã³ïŒåŒïŒ
ïŒïŒšïŒR1ïŒCH3ïŒãæ²¹ãn20 DïŒ1.6014ïŒ ïŒâïŒïŒïŒïŒâãžã¡ãã«âïŒâããããã·âïŒ
âããšãã«ïŒâïŒâããšãã«âïŒâããããã³
ïŒåŒïŒïŒ²åã³R1ïŒCH3ïŒãèç¹ïŒãã«ãšã³ïŒãš
ãŒãã«ïŒïŒ43ã46âã ç©è³ªã®æäžæŽèèœåãç 究ãããšãã«ã¯ãè©Šéš
äžã®ååç©ã®æäžåŸã®å¿å®€ã®ç°ææååã¯å¿å®€çŽ°
åã®æžå°ã«ããä¿è·ã枬å®ããããç æŽã«ãã
ãããããã®åç©ããããèªèº«ã§å¯Ÿç §çšã«ãã
ããããªãã¡åç©ã¯å¯Ÿç §çŸ€åã³åŠçœ®çŸ€ã®ïŒçŸ€ã«å
ããããã ãããã®ååç©ã¯äºæ€æè¡ãšããŠäœ¿çšãããç°
ãªãå®éšçäžæŽèã¢ãã«ã«ããããããã®æŽ»æ§ã«
åŸã€ãŠãŸãéžæããããããã§ã¯ãããã«ã ãã¢
ã³ããã³åã³å¡©åã«ã«ã·ãŠã è©ŠéšããJ.W.ããŒ
ãœã³ïŒLawsonïŒèãJ.Pharmacol.exp.
Ther.160ïŒ22ã81ïŒ1968ïŒâã¯ã€ãããã¿äžã®æ¥
éäºæ€æ¹æ³ã«ãã枬å®ãããããçš®ã®ã€ãœãããª
ã³èªå°äœã®æäžæŽè掻æ§âã«èšãããŠããããã«
æ¬çºæã®ååç©ã®è©Šéšçšã«äœ¿çšãããã ã³ãŒãçªå·ïŒ LG80âïŒâ00ïŒïŒâãïŒâïŒïŒâããããã·â
ïŒâïœâããã«ã¢ããããããã·ïŒâïŒâã
ãšãã«ãâïŒâããšãã«âïŒâããããã³â
ã¯ããããã¬ãŒã LG80âïŒâ01ïŒïŒâãïŒâã¡ãã«âïŒâïŒïŒâ
ããããã·âïŒâïœâãããã«ã¢ããããã
ãã·ïŒâïŒâããšãã«ãâïŒâããšãã«âïŒâ
ããããã³âã¯ããããã¬ãŒãã LG80âïŒâ02ïŒïŒâãïŒâã¡ãã«âïŒâïŒïŒâ
ããããã·âïŒâïœâãããã«ã¢ããããã
ãã·ïŒâïŒâããšãã«ãâïŒâããšãã«âïŒâ
ããããã³âã¯ããããã¬ãŒã Prop.ïŒãããããšãã³ã ã¯ãããã«ã è©Šéš ç 究äžã®ååç©ã®éè泚å°ã®ïŒååŸã«ãã¯ã€ã
ããã¿ã20mlã®ã¯ãããã«ã ã«æµžãããŠããã³ã
ãã³ãŠãŒã«ãå«ãã§ãã300mlã®ããŒã«ãŒäžã«ã
ãããåç©ã泚æããŠèŠ³å¯ããããŠç¬¬äºã®åŒåžå
æ¢ãçãããåŠãããŒã«ãŒãããšãåºããã次ã«
å¿èãéããã«å¿å®€æ¶ç©ã®å¯èŠçæ€æ»ã«ããã
ïŒããŒãœã³ãåŒçšæç®åç §ïŒãED50ã¯ã¯ãããã«
ã ã«ããèªçºãããå¿å®€çŽ°åã«å¯ŸããŠã¯ã€ããã
ã¿ã®50ïŒ ãä¿è·ãããããªååç©ã®æäžéã§ã
ããäžè¡šã¯æ°èŠååç©ã§ããLG80âïŒâ00ã
LG81âïŒâ01ãLG81âïŒâ02䞊ã³ã«åç §ååç©
ã§ãããããããšãã³ã®ED50ã瀺ããŠããã ã¢ã³ããã³è©Šéš ã¢ã³ããã³ã«ããèªçºãããäžæŽèã«å¯Ÿããå
åç©ã®ä¿è·å¹æãç 究ããããã«ã¯ç 究è éã¯ã
ãã¿ã奜ãããã§ãããJ.L.ãžãŠãã¢ã³
ïŒJunienïŒä»èãArzneimãForsch.24ïŒ1743ã
1747ïŒ1974ïŒïŒL.ãŒã±ã¬ã¹ïŒSzekeresïŒä»èãå®
éšçå¿èäžæŽèåã³æäžæŽèè¬ããããªãã·ã³
ã°ã»ããŠã¹ã»ãªãã»ã¶ã»ãã³ã¬ãªã¢ã³ã»ã¢ã«ãã
ã€ã»ãªãã»ãµã€ãšã³ã»ã¹ïŒAkademia KiadoïŒã
ãã¿ãã¹ãïŒ1971ïŒïŒM.R.ããªããŠïŒMalinowïŒ
ä»èãArch.int.Pharmacodyn.102ïŒ55ã64
ïŒ1955ïŒïŒC.ãã¢ã³ãïŒBianchiïŒä»èãArzneim.
Forsch.18ïŒ845ã850ïŒ1968ïŒïŒB.B.ãã«ã¬ããã€
ããïŒVargaftigïŒä»èãJ.Pharm.Pharmacl.27ïŒ
697ã699ïŒ1975ïŒïŒåã³M.ããšã±ãïŒFeketeïŒä»
èãMed.Exp.10ïŒ93ã102ïŒ1964ïŒåç §ãã è©Šéšååç©ããŠã¬ã¿ã³ã§éº»é ããããããã¿
ã«ãã¢ã³ããã³ã®æ³šå°åã«æäžãããçš®ã ã®æäž
æŽèè¬ã¯ã¢ã³ããã³èªçºæ§äžæŽèã®éå§ãé ãã
ããšãã§ãããããŠãã®äžæŽèã®ã¢ãã«ã¯æäžæŽ
è掻æ§ãè©äŸ¡ããã®ã«é©ããŠããããã§ããã äžè¡šã¯LG80âïŒâ00ãLG81âïŒâ01ãLG81
âïŒâ02䞊ã³ã«ãããããšãã³ã®ED50ã«é¢ãã
è©Šéšçµæã瀺ããŠããããã®æ¹æ³ã§æè¯ã®ååç©
ã¯LG81âïŒâ01ã§ããããšãæçœã§ããã å¡©åã«ã«ã·ãŠã è©Šéš è¡æž ã€ãªã³æ°Žæºãç°åžžã§ãããšãã«ãç¹ã«ã«ã«
ã·ãŠã æ°Žæºãæ£åžžã®æ¿åºŠããïŒåã»ã©é«ããšã
ã«ããã°ãã°å¿èäžæŽèãèµ·ãããããã¯å¡©åã«
ã«ã·ãŠã ã®é«æçšéã®éèå æäžããªãåç©äžã®
åŸåäžæŽã®çºéãèªçºã§ããçç±ã§ããã麻é ã
ãããããããã¿ã§ã¯å¡©åã«ã«ã·ãŠã ã®æ¥éãªé
è泚å°ã¯èŽæ»æ§ã®å¿å®€çŽ°ååã¯å¿å®€æå€åçž®ãç
ãããå¡©åã«ã«ã·ãŠã 泚å°ã®åã«æäžãããè©Šéš
ååç©ã®æŽ»æ§ã®è©äŸ¡ã¯äžæŽèã®éå§ãåºã«ããŠã
ããM.R.ããªããŠä»èArch.int.
Pharmacodyn.102ïŒ55ã64ïŒ1955ïŒâããã¿ã«ã
ããå®éšçå¿å®€äžæŽèã®è¬çåŠãæãã¹ã¿ãã³
å€âããæãã¯æã ã®åŸåé害åŸã®æŽåŸåãžã®æ»
ããåºã«ããŠãããM.ããšã±ãä»èMed.
Exp.10ïŒ93ã102ïŒ1964ïŒâããçš®ã®ãã¢ã¬ããã€
ãã¯ïŒthymolepticsïŒã¢ãããªãããªã³ãã€ãã
ã©ãã³ãããªã¡ããããã³åã³ãã¹ã¡ãã«ã€ãã
ã©ãã³ãã®æäžæŽèå¹æã«é¢ããŠâãã æ¬çºæã®ååç©ã¯å¡©åã«ã«ã·ãŠã èªçºãããäž
æŽèã«å¯ŸããŠä¿è·å¹æãæããããšã瀺ãããŠã
ããå¯Ÿç §çšååç©ã§ãããããããšãã³ãšæ¯èŒã
ãŠã®æ¬çºæã®ååç©ã®ED50ãäžè¡šã«ç€ºããLG81
âïŒâ01ãå¡©åã«ã«ã·ãŠã ã«ããèªçºãããäžæŽ
èã«å¯ŸããŠæè¯ã®ä¿è·ãäžããããšãæçœã§ã
ãã
åŒ ãåŒäžãåã³R1ã¯ç¬ç«ããŠæ°ŽçŽ åã¯ã¡ãã«
ã§ããããã㊠R2ã¯ïœâãããã«ãïœâããã«ãã€ãœããã«
åã¯ã¿ãŒã·ã€ãªãŒâããã«ã§ããã ã®ïŒâãïŒâïŒïŒâããããã·âïŒâã¢ã«ãã«ã¢ã
ãããããã·ïŒâïŒâããšãã«ãâïŒâããšãã«â
ïŒâããããã³ã®æ°èŠèªå°äœåã³ãããã®é žä»å
å¡©ããããã®è£œé æ¹æ³åã³ãããæå¹æåãšããŠ
å«æããæäžæŽèè¬ã«é¢ããã æ¬çºæã®æ¹æ³ã¯ãäžè¬åŒ ãåŒäžãåã³R1ã¯äžèšã§å®çŸ©ãããŠããåŠ
ãã§ããããã㊠Meã¯ã¢ã«ã«ãªéå±ã®ã«ããªã³ã§ããã ã®ååç©ãåŒ ã®ãšãã¯ãããããªã³ãšåå¿ããããããŠãã®ã
ãã«ããŠåŸãããåŒ ãåŒäžãåã³R1ã¯äžèšã§å®çŸ©ãããŠããåŠ
ãã§ããã ã®ååç©ãäžè¬åŒ R2âNH2 ïŒïŒ ãåŒäžãR2ã¯äžèšã§å®çŸ©ãããŠããåŠãã§ã
ãã ã®ã¢ã«ãã«ã¢ãã³ãšåå¿ããããããŠåžæãããª
ãåŸãããåŒïŒïŒã®å¡©åºãé žä»å å¡©ã«è»¢åãã
ããšãããªã€ãŠããã äžè¬åŒïŒïŒã®æ°èŠååç©ã¯çš®ã ãªåç©ã¢ãã«
ïŒanimal modelsïŒã«å¯ŸããŠäœãæäžéã§ãã§ã«
é¡èãªæäžæŽè掻æ§ãæããããããã¯çµå£æäž
ããæã«ã掻æ§ã§ããã 奜é©ãªçš®é¡ã¯R2ãïœâãããã«ã§ããåŒïŒïŒ
ã®ååç©ã®ãã®ã§ããã ãããã®è£œè¬åŠçæ§è³ªã®ããã«ãæ°èŠååç©å
ã³ãããã®é žä»å å¡©ã¯åç¬ã§åã¯ä»ã®æŽ»æ§ç©è³ªãš
æ··åããŠãå¿æé害ã®æ²»ççšã®æ®éã®è£œå€ã®åœ¢ã§
ïŒåã³é 延圢ã§ïŒäœ¿çšã§ããã æ¬çºæã«åŸãååç©ïŒïŒãšååç©ïŒïŒã®å
å¿ã¯å¥œé©ã«ã¯äžæŽ»æ§æº¶åªäžã§ãç¹ã«å¥œé©ã«ã¯éå°
éã®ãšãã¯ãããããªã³äžã§ã110ã140âã®éã®
枩床ã«ãããŠå®æœãããã äžéçæç©ååç©ïŒïŒãšååç©ïŒïŒã®åå¿
ã¯å¥œé©ã«ã¯äžæŽ»æ§æº¶åªäžã§ãç¹ã«å¥œé©ã«ã¯éå°é
ã®ã¢ãã³ïŒïŒäžã§ã50ã100âã®éã®æž©åºŠã«ã
ããŠå®æœãããã åŒïŒïŒã®ååç©ã®é žä»å å¡©ã¯ããèªäœã¯å ¬ç¥
ã®æ¹æ³ã§ãäŸãã°ã¢ã«ã«ãªåã¯ã€ãªã³äº€æäœãçš
ããŠãéé¢å¡©åºã«è»¢åã§ãããç¡æ©åã¯ææ©é žã
ç¹ã«æ²»çäžæçšãªå¡©ãçæããã®ã«é©ãããã®ã
ãšã®åå¿ã«ããäžèšã®å¡©åºããä»ã®å¡©ãååã§ã
ãã æ°èŠååç©ãšãããã®å¡©ãšã®éã®è¿ãé¢ä¿ã®ã
ãã«ããéé¢å¡©åºããšããè¡šçŸã¯å¯Ÿå¿ããå¡©ãå
æ§ã«ãããŠäžè¬çã«å å«ããŠããã åŒïŒïŒåã³ïŒïŒã®åºçºç©è³ªã¯æç®ããå ¬ç¥
ã§ããã åŒïŒïŒã®ååç©ã¯éé¢ååç©ïŒMeïŒïŒšïŒã
ããæã簡䟿ã«ã¯ã¢ã«ã«ãªæ§æ°Žé žåç©ãã¢ã«ã«ãª
æ§æ°ŽçŽ åç©åã¯ã¢ã«ã«ãªæ§ã¢ã«ã³ã¬ãŒããçšããŠ
補é ã§ããã åŒïŒïŒã®éé¢ååç©ã¯åŒïŒïŒã®å ¬ç¥ã®åå
ç©ããåºçºããŠäžèšã®åå¿åŒã«åŸã補é ã§ããïŒ å®æœäŸ ïŒâãïŒâïŒïŒïŒïŒâãšããã·ããããã·ïŒâ
ïŒâããšãã«ãâïŒâããšãã«âïŒâãããã
ã³ïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒ 1.74ïœïŒ0.076ã¢ã«ïŒã®ãããªãŠã ã50mlã®ç¡
æ°Žã¡ã¿ããŒã«äžã®æº¶è§£ããã17.55ïœïŒ0.076ã¢
ã«ïŒã®ïŒâïŒïŒâããããã·âïŒâããšãã«ïŒœâïŒ
âããšãã«âïŒâããããã³ïŒåŒïŒïŒ²åã³R1
ïŒïŒšïŒMeïŒïŒšïŒãå ãããããŠæº¶æ¶²ãèžçºïŒç
空äžïŒä¹Ÿåºããã50mlã®ãšãã¯ãããããªã³
ïŒïŒãçµæ¶æ§æ®æž£ïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒMe
ïŒNaïŒã«å ãããããŠïŒæééæµããããåå¿
æ··åç©ããã€ããäžã§éããå°éã®ãã³ãŒã³ã§
ãããããããŠæ¶²ãç空äžã§èžçºããããçµæ¶
æ§æ®æž£ãççŽ ãæ·»å ãããŠãã1250mlã®ã·ã¯ãã
ããµã³äžã§å ç±ãããã€ããäžã§éãããããŠ
液ãç空äžã§èžçºããããçµæ¶æ§æ®æž£ã®ééã¯
16.9ïœïŒ77.6ïŒ ïŒã§ãã€ããçæç©ã¯ãã®åŸäœ¿çš
ããã®ã«å åãªã»ã©ã®çŽåºŠã§ãã€ããèç¹ïŒã·ã¯
ããããµã³ïŒ59ã61âã åæ§ã«ããŠäžèšã®ååç©ã補é ã§ããã ïŒâãïŒâïŒïŒïŒïŒâãšããã·ããããã·ïŒâïŒ
âã¡ãã«âïŒâããšãã«ãâïŒâããšãã«âïŒâ
ããããã³ïŒåŒïŒïŒ²ïŒCH3ïŒR1ïŒïŒšïŒãæ²¹ãå
é¢ãããïŒïŒâãïŒâïŒïŒïŒïŒâãšããã·ãããã
ã·ïŒâïŒâã¡ãã«âïŒâããšãã«ãâïŒâããšãã«
âïŒâããããã³ïŒåŒïŒïŒ²ïŒïŒšïŒR1ïŒCH3ïŒã
æ²¹ãåé¢ãããïŒïŒâãïŒïŒïŒâãžã¡ãã«âïŒâ
ïŒïŒïŒïŒâãšããã·ããããã·ïŒâïŒâããšãã«ã
âïŒâããšãã«âïŒâããããã³ïŒåŒïŒïŒ²åã³
R1AïŒCH3ïŒãæ²¹ãåé¢ããããn20 DïŒ1.5535ã ïŒâãïŒâïŒïŒâããããã·âïŒâïœâãããã«
ã¢ããããããã·ïŒâïŒâããšãã«ãâïŒâããšã
ã«âïŒâããããã³âã¯ããããã¬ãŒãïŒåŒïŒ
HClïŒïŒ²åã³R1ïŒïŒšïŒR2ïŒïœâãããã«ïŒ 14.4ïœïŒ0.05ã¢ã«ïŒã®ç²ïŒâãïŒâïŒïŒïŒïŒâãš
ããã·ããããã·ïŒâïŒâããšãã«ãâïŒâããšã
ã«âïŒâããããã³ïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒã
40mlã®ïœâãããã«ã¢ãã³ïŒåŒïŒR2ïŒããã
ã«ïŒäžã§æ¹æããªããïŒæéã«ããã€ãŠéæµãã
ããåå¿æ··åç©ãç空äžã§èžçºãããæ®æž£ã250
mlã®CH2Cl2åã³150mlã®1Nå¡©é žã®éã«åé ããã
çžãåé¢ããæ°ŽçžãïŒÃ50mlã®CH2Cl2ã§æœåºãã
äžç·ã«ããææ©çžã也ç¥ãïŒNa2SO4ïŒããããŠ
ç空äžã§èžçºããããçµæ¶åœ¢ã§åŸãããç²çæç©
ãççŽ ã§å«ãã§ããã¢ã»ãã³ïŒã¡ã¿ããŒã«ïŒïŒïŒ
ïŒçŽ120mlïŒããåçµæ¶åãããããšãã§ãããå
éã12.2ïœïŒ64ïŒ ïŒã®ç¡è²ã®çµæ¶ãèç¹150ã152
âã åæ§ãªæ¹æ³ã§äžèšã®ååç©ãåŸãããïŒ ïŒâãïŒâïŒïŒâããããã·âïŒâïœâããã«ã¢
ããããããã·ïŒâïŒâããšãã«ãâïŒâããšãã«
âïŒâããããã³âã¯ããããã¬ãŒãïŒåŒïŒïŒ²
åã³R1ïŒïŒšïŒR2ïŒïœâããã«ïŒãèç¹ïŒã¢ã»ãã³
ããïŒïŒ113ã114âïŒ ïŒâãïŒâïŒïŒâããããã·âïŒâïœâã¿ãŒã·ã€
ãªãŒâããã«ã¢ããããããã·ïŒâïŒâããšãã«ã
âïŒâããšãã«âïŒâããããã³âã¯ããããã¬
ãŒãïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒR2ïŒã¿ãŒã·ã€ãªãŒ
âããã«ïŒãèç¹ïŒã¢ã»ãã³ããïŒïŒ143ã144âïŒ ïŒâãïŒâã¡ãã«âïŒâïŒïŒâããããã·âïŒâ
ïœâãããã«ã¢ããããããã·ïŒâïŒâããšãã«ã
âïŒâããšãã«âïŒâããããã³âã¯ããããã¬
ãŒãïŒåŒïŒïŒ²ïŒCH3ïŒR1ïŒïŒšïŒR2ïŒïœâãã
ãã«ïŒãèç¹107ã111âïŒã¡ã¿ããŒã«ïŒãšãŒã
ã«ïŒïŒ ïŒâãïŒâã¡ãã«âïŒâïŒïŒâããããã·âïŒâ
ïœâãããã«ã¢ããâããããã·ïŒâïŒâããšã
ã«ãâïŒâããšãã«âïŒâããããã³âã¯ããã
ãã¬ãŒãïŒåŒïŒïŒ²ïŒïŒšïŒR1ïŒCH3ïŒR2ïŒïœâ
ãããã«ïŒãèç¹ïŒ203ã205âïŒã¡ã¿ããŒã«ã
ãïŒïŒïŒâãïŒïŒïŒâãžã¡ãã«âïŒâïŒïŒâããã
ãã·âïŒâïœâãããã«ã¢ããããããã·ïŒâïŒ
âããšãã«ãâïŒâããšãã«âïŒâããããã³â
ã¯ããããã¬ãŒãïŒåŒïŒïŒ²åã³R1ïŒCH3ïŒR2
ïŒïœâãããã«ïŒãèç¹ïŒ126ã128âïŒãã«ãš
ã³ïŒãšãŒãã«ïŒã åºçºååç©ã¯äžèšã®åŠãããŠåŸãããã ïŒâã¡ããã·âããªããšã³âïŒâã«ã«ãã³é ž
ïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒ 13.5ïœïŒ0085ã¢ã«ïŒã®ïŒâããããã·ããªããš
ã³âïŒâã«ã«ãã³é žã¡ãã«ãšã¹ãã«ïŒïŒïŒ²åã³
R1ïŒïŒšïŒã36ïœïŒ0.34ã¢ã«ïŒã®Na2CO3ã®145ml
ã®H2Oäžæº¶æ¶²ã«å ãããããŠæ¹æããªããçæ
é沞ãšããããã次ã«15å以å ã«21.53ïœïŒ0.17
ã¢ã«ïŒã®ç¡«é žãžã¡ãã«ãããã«æ»Žäžãããã®éå
å¿æ··åç©ã®æž©åºŠã¯æ²žç¹ã®ããäžã«ä¿ã€ããæ·»å ã®
å®äºåŸã«ãå ç±ãéæµäžã§20åéç¶ããåå¿æ··å
ç©ãå·åŽããããŠCH2Cl2ã§ïŒãïŒåæœåºããã
äžç·ã«ããææ©çžã2NNaOHã§ïŒåæœåºãã也
ç¥ãïŒNa2SO4ïŒããããŠèžçºããããïŒâã¡ã
ãã·âããªããšã³âïŒâã«ã«ãã³é žã¡ãã«ãšã¹ã
ã«ïŒïŒïŒ²åã³R1ïŒïŒšïŒãããªãæ²¹ç¶æ®æž£ã¯7.1
ïœã®ééãæããŠããããã®æ®æž£ã2.54ïœ
ïŒ0.045ã¢ã«ïŒã®KOHã®70mlã®ã¡ã¿ããŒã«äžæº¶æ¶²
ã®äžã«æº¶è§£ããããããŠ30åééæµãããã次ã«
ã¡ã¿ããŒã«ãç空äžã§èžçé€å»ãããããŠæ®æž£ã
æ°ŽãšCH2Cl2ã®éã«åé ããããæ°Žçžãæ¿HClã§
é žæ§åãããããŠæ²æ®¿ããç¡è²ã®çµæ¶ãå¥ã
ããåéïŒ5.7ïœïŒ54ïŒ ïŒãèç¹180ã183âã åæ§ãªæ¹æ³ã§äžèšã®ååç©ã補é ã§ããïŒ ïŒâã¡ããã·âïŒâã¡ãã«âããªããšã³âïŒâ
ã«ã«ãã³é žïŒåŒïŒïŒ²ïŒCH3ïŒR1ïŒïŒšïŒãèç¹ïŒ
119ã121âïŒ ïŒâã¡ããã·âïŒâã¡ãã«âããªããšã³âïŒâ
ã«ã«ãã³é žïŒåŒïŒïŒ²ïŒïŒšïŒR1ïŒCH3ïŒãèç¹ïŒ
175ã177âïŒ ïŒïŒïŒâãžã¡ãã«âïŒâã¡ããã·âããªããšã³
âïŒâã«ã«ãã³é žïŒåŒïŒïŒ²ïŒR1ïŒCH3ïŒãè
ç¹ïŒ133ã135âã ïŒâã¡ããã·ããªããšã³ïŒïŒïŒ²åã³R1ïŒïŒšïŒ 57ïœã®ïŒâã¡ããã·ããªããšã³âïŒâã«ã«ãã³
é žïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒã15ïœã®Cuâç²æ«ãš
å ±ã«ç åãããããŠåéæ段ãæããèžçã³ã³ã
ã³ãµãšé£çµããŠããèžçãã©ã¹ã³äžã«ç§»ãããè£
眮äžã«65mmHgã®ç空ãé©çšãããããŠèžçãã©
ã¹ã³ã150ã180âã«å ç±ãããèžçããïŒâã¡ã
ãã·ããªããšã³ãåéè£ çœ®äžã«éãããåéïŒ33
ïœïŒ80ïŒ ïŒã åæ§ãªæ¹æ³ã§äžèšã®ååç©ãåŸãããã ïŒâã¡ããã·âïŒâã¡ãã«âããªããšã³ïŒåŒ
ïŒïŒ²ïŒCH3ïŒR1ïŒïŒšïŒã沞ç¹ïŒ83âïŒ30mm
HgïŒ ïŒâã¡ããã·âïŒâã¡ãã«âããªããšã³ïŒåŒ
ïŒïŒ²ïŒïŒšïŒR1ïŒCH3ïŒã沞ç¹ïŒ63ã65âïŒ16ã
ãªããŒã«ïŒ ïŒïŒïŒâãžã¡ããã·âïŒâã¡ããã·âããªããš
ã³ïŒåŒïŒïŒ²åã³R1ïŒCH3ïŒã沞ç¹ïŒ78ã84âïŒ
10mmHgã ïŒâïŒïŒâããããã·âïŒâããšãã«ïŒâïŒâã
ãšãã«âïŒâããããã³ïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒ 44.9ïœïŒ0.266ã¢ã«ïŒã®ããšãã«ããããªã³é ž
ã¯ãã©ã€ãã400mlã®ç¡æ°ŽCHCl3äžã«æº¶è§£ãããã
次ã«50mlã®CHCl3äžã®69.37ïœïŒ0.266ã¢ã«ïŒã®
SnCl4ãããã«æ»Žäžããã次ã«ãæ··åç©ã®æž©åºŠã
15âã«é«ãããããŠ250mlã®CHCl3äžã«æº¶è§£ãã
ãŠãã30.4ïœïŒ0.266ã¢ã«ïŒã®ïŒâã¡ããã·ããª
ããšã³ïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒã30å以å ã«ã
ãã«æ»Žäžãããæ¹æã20åéç¶ãããåå¿æ··åç©
ãäžçšåºŠã®æ¿HClã«æ³šããææ©çžãåé¢ãããã
ãŠCH2Cl2ã§ïŒåæœåºãããäžç·ã«ããææ©çžã
NaHCO3ã®æº¶æ¶²ã§ïŒåæœåºãã也ç¥ã
ïŒNa2SO4ïŒããããŠèžçºããããäž»ãšããŠïŒâ
ïŒïŒâã¡ããã·âïŒâããšãã«ïŒâïŒâããšãã«â
ïŒâããããã³ïŒåŒïŒïŒ²åã³R1ïŒïŒšïŒãããª
ãæ²¹ç¶æ®æž£ïŒ57ïŒ ïŒã270mlã®ããããã³ãŒã³äž
ã«æº¶è§£ããããããŠ62ïœã®ç¡æ°ŽAlCl3ã®270mlã®
ããããã³ãŒã³äžæº¶æ¶²ã«å ãããåå¿æ··åç©ã70
ã90âã§1.5æéæ¹æããå·åŽããæ°·ïŒHClã«æ³š
ãããããŠå®€æž©ã§äžå€æŸçœ®ããã次ã«çžãåé¢
ããæ°ŽçžãCH2Cl2ã§ïŒåæœåºããäžç·ã«ããæ
æ©çžã2NNaOHã§ïŒåæœåºããäžç·ã«ãã
NaOHâçžãæ¿HClã§é žæ§åãããããŠæ²æ®¿ãã
çæç©ãCH2Cl2ã§ïŒåæœåºãããäžç·ã«ãã
CH2Cl2âçžãèžçºãããåŸã«ãæ¿è²ã®çµæ¶æ§æ®
枣ããã³ãŒã³äžã«æº¶è§£ãããã·ãªã«ã²ã«äžã§é
ãããããŠå åæŽæµããã液ã®èžçºåŸã«ã29.1
ïœïŒ47ïŒ ïŒã®çŽç²ãªçæç©ãåŸãããã èç¹ïŒã¡ã¿ããŒã«ïŒïŒ50âã åæ§ãªæ¹æ³ãäžèšã®ååç©ãåŸãããïŒ ïŒâïŒïŒâããããã·âïŒâã¡ãã«âïŒâããš
ãã«ïŒâïŒâããšãã«âïŒâããããã³ïŒåŒã
ïŒCH3ïŒR1ïŒïŒšïŒãèç¹ïŒ36ã38âïŒã¡ã¿ããŒ
ã«ïŒïŒ ïŒâïŒïŒâããããã·âïŒâã¡ãã«âïŒâããš
ãã«ïŒâïŒâããšãã«âïŒâããããã³ïŒåŒïŒ
ïŒïŒšïŒR1ïŒCH3ïŒãæ²¹ãn20 DïŒ1.6014ïŒ ïŒâïŒïŒïŒïŒâãžã¡ãã«âïŒâããããã·âïŒ
âããšãã«ïŒâïŒâããšãã«âïŒâããããã³
ïŒåŒïŒïŒ²åã³R1ïŒCH3ïŒãèç¹ïŒãã«ãšã³ïŒãš
ãŒãã«ïŒïŒ43ã46âã ç©è³ªã®æäžæŽèèœåãç 究ãããšãã«ã¯ãè©Šéš
äžã®ååç©ã®æäžåŸã®å¿å®€ã®ç°ææååã¯å¿å®€çŽ°
åã®æžå°ã«ããä¿è·ã枬å®ããããç æŽã«ãã
ãããããã®åç©ããããèªèº«ã§å¯Ÿç §çšã«ãã
ããããªãã¡åç©ã¯å¯Ÿç §çŸ€åã³åŠçœ®çŸ€ã®ïŒçŸ€ã«å
ããããã ãããã®ååç©ã¯äºæ€æè¡ãšããŠäœ¿çšãããç°
ãªãå®éšçäžæŽèã¢ãã«ã«ããããããã®æŽ»æ§ã«
åŸã€ãŠãŸãéžæããããããã§ã¯ãããã«ã ãã¢
ã³ããã³åã³å¡©åã«ã«ã·ãŠã è©ŠéšããJ.W.ããŒ
ãœã³ïŒLawsonïŒèãJ.Pharmacol.exp.
Ther.160ïŒ22ã81ïŒ1968ïŒâã¯ã€ãããã¿äžã®æ¥
éäºæ€æ¹æ³ã«ãã枬å®ãããããçš®ã®ã€ãœãããª
ã³èªå°äœã®æäžæŽè掻æ§âã«èšãããŠããããã«
æ¬çºæã®ååç©ã®è©Šéšçšã«äœ¿çšãããã ã³ãŒãçªå·ïŒ LG80âïŒâ00ïŒïŒâãïŒâïŒïŒâããããã·â
ïŒâïœâããã«ã¢ããããããã·ïŒâïŒâã
ãšãã«ãâïŒâããšãã«âïŒâããããã³â
ã¯ããããã¬ãŒã LG80âïŒâ01ïŒïŒâãïŒâã¡ãã«âïŒâïŒïŒâ
ããããã·âïŒâïœâãããã«ã¢ããããã
ãã·ïŒâïŒâããšãã«ãâïŒâããšãã«âïŒâ
ããããã³âã¯ããããã¬ãŒãã LG80âïŒâ02ïŒïŒâãïŒâã¡ãã«âïŒâïŒïŒâ
ããããã·âïŒâïœâãããã«ã¢ããããã
ãã·ïŒâïŒâããšãã«ãâïŒâããšãã«âïŒâ
ããããã³âã¯ããããã¬ãŒã Prop.ïŒãããããšãã³ã ã¯ãããã«ã è©Šéš ç 究äžã®ååç©ã®éè泚å°ã®ïŒååŸã«ãã¯ã€ã
ããã¿ã20mlã®ã¯ãããã«ã ã«æµžãããŠããã³ã
ãã³ãŠãŒã«ãå«ãã§ãã300mlã®ããŒã«ãŒäžã«ã
ãããåç©ã泚æããŠèŠ³å¯ããããŠç¬¬äºã®åŒåžå
æ¢ãçãããåŠãããŒã«ãŒãããšãåºããã次ã«
å¿èãéããã«å¿å®€æ¶ç©ã®å¯èŠçæ€æ»ã«ããã
ïŒããŒãœã³ãåŒçšæç®åç §ïŒãED50ã¯ã¯ãããã«
ã ã«ããèªçºãããå¿å®€çŽ°åã«å¯ŸããŠã¯ã€ããã
ã¿ã®50ïŒ ãä¿è·ãããããªååç©ã®æäžéã§ã
ããäžè¡šã¯æ°èŠååç©ã§ããLG80âïŒâ00ã
LG81âïŒâ01ãLG81âïŒâ02䞊ã³ã«åç §ååç©
ã§ãããããããšãã³ã®ED50ã瀺ããŠããã ã¢ã³ããã³è©Šéš ã¢ã³ããã³ã«ããèªçºãããäžæŽèã«å¯Ÿããå
åç©ã®ä¿è·å¹æãç 究ããããã«ã¯ç 究è éã¯ã
ãã¿ã奜ãããã§ãããJ.L.ãžãŠãã¢ã³
ïŒJunienïŒä»èãArzneimãForsch.24ïŒ1743ã
1747ïŒ1974ïŒïŒL.ãŒã±ã¬ã¹ïŒSzekeresïŒä»èãå®
éšçå¿èäžæŽèåã³æäžæŽèè¬ããããªãã·ã³
ã°ã»ããŠã¹ã»ãªãã»ã¶ã»ãã³ã¬ãªã¢ã³ã»ã¢ã«ãã
ã€ã»ãªãã»ãµã€ãšã³ã»ã¹ïŒAkademia KiadoïŒã
ãã¿ãã¹ãïŒ1971ïŒïŒM.R.ããªããŠïŒMalinowïŒ
ä»èãArch.int.Pharmacodyn.102ïŒ55ã64
ïŒ1955ïŒïŒC.ãã¢ã³ãïŒBianchiïŒä»èãArzneim.
Forsch.18ïŒ845ã850ïŒ1968ïŒïŒB.B.ãã«ã¬ããã€
ããïŒVargaftigïŒä»èãJ.Pharm.Pharmacl.27ïŒ
697ã699ïŒ1975ïŒïŒåã³M.ããšã±ãïŒFeketeïŒä»
èãMed.Exp.10ïŒ93ã102ïŒ1964ïŒåç §ãã è©Šéšååç©ããŠã¬ã¿ã³ã§éº»é ããããããã¿
ã«ãã¢ã³ããã³ã®æ³šå°åã«æäžãããçš®ã ã®æäž
æŽèè¬ã¯ã¢ã³ããã³èªçºæ§äžæŽèã®éå§ãé ãã
ããšãã§ãããããŠãã®äžæŽèã®ã¢ãã«ã¯æäžæŽ
è掻æ§ãè©äŸ¡ããã®ã«é©ããŠããããã§ããã äžè¡šã¯LG80âïŒâ00ãLG81âïŒâ01ãLG81
âïŒâ02䞊ã³ã«ãããããšãã³ã®ED50ã«é¢ãã
è©Šéšçµæã瀺ããŠããããã®æ¹æ³ã§æè¯ã®ååç©
ã¯LG81âïŒâ01ã§ããããšãæçœã§ããã å¡©åã«ã«ã·ãŠã è©Šéš è¡æž ã€ãªã³æ°Žæºãç°åžžã§ãããšãã«ãç¹ã«ã«ã«
ã·ãŠã æ°Žæºãæ£åžžã®æ¿åºŠããïŒåã»ã©é«ããšã
ã«ããã°ãã°å¿èäžæŽèãèµ·ãããããã¯å¡©åã«
ã«ã·ãŠã ã®é«æçšéã®éèå æäžããªãåç©äžã®
åŸåäžæŽã®çºéãèªçºã§ããçç±ã§ããã麻é ã
ãããããããã¿ã§ã¯å¡©åã«ã«ã·ãŠã ã®æ¥éãªé
è泚å°ã¯èŽæ»æ§ã®å¿å®€çŽ°ååã¯å¿å®€æå€åçž®ãç
ãããå¡©åã«ã«ã·ãŠã 泚å°ã®åã«æäžãããè©Šéš
ååç©ã®æŽ»æ§ã®è©äŸ¡ã¯äžæŽèã®éå§ãåºã«ããŠã
ããM.R.ããªããŠä»èArch.int.
Pharmacodyn.102ïŒ55ã64ïŒ1955ïŒâããã¿ã«ã
ããå®éšçå¿å®€äžæŽèã®è¬çåŠãæãã¹ã¿ãã³
å€âããæãã¯æã ã®åŸåé害åŸã®æŽåŸåãžã®æ»
ããåºã«ããŠãããM.ããšã±ãä»èMed.
Exp.10ïŒ93ã102ïŒ1964ïŒâããçš®ã®ãã¢ã¬ããã€
ãã¯ïŒthymolepticsïŒã¢ãããªãããªã³ãã€ãã
ã©ãã³ãããªã¡ããããã³åã³ãã¹ã¡ãã«ã€ãã
ã©ãã³ãã®æäžæŽèå¹æã«é¢ããŠâãã æ¬çºæã®ååç©ã¯å¡©åã«ã«ã·ãŠã èªçºãããäž
æŽèã«å¯ŸããŠä¿è·å¹æãæããããšã瀺ãããŠã
ããå¯Ÿç §çšååç©ã§ãããããããšãã³ãšæ¯èŒã
ãŠã®æ¬çºæã®ååç©ã®ED50ãäžè¡šã«ç€ºããLG81
âïŒâ01ãå¡©åã«ã«ã·ãŠã ã«ããèªçºãããäžæŽ
èã«å¯ŸããŠæè¯ã®ä¿è·ãäžããããšãæçœã§ã
ãã
ãè¡šã
æ¬çºæã®ååç©ã人éã®äžæŽèã®æ²»çã«çšãã
ãšãã®æäžéã¯ãçµå£æäžã®å ŽåïŒã20mgïŒKgã
éèå 泚å°ã®å ŽåïŒãïŒmgïŒKgã§ãããLG81â
ïŒâ01ã«ã€ããŠã®æ¥æ§æ¯æ§è©Šéšã®çµæãäžè¡šã«ç€º
ãã
ãšãã®æäžéã¯ãçµå£æäžã®å ŽåïŒã20mgïŒKgã
éèå 泚å°ã®å ŽåïŒãïŒmgïŒKgã§ãããLG81â
ïŒâ01ã«ã€ããŠã®æ¥æ§æ¯æ§è©Šéšã®çµæãäžè¡šã«ç€º
ãã
ãè¡šã
ïŒïŒéãïŒé
LD50ïŒãªãããã€ãŒã«ãã»ãŠã€ã«ã³ã¯ãœã³æ³ã«
ããç®å®
ããç®å®
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äžè¬åŒ åŒäžãåã³R1ã¯ç¬ç«ããŠæ°ŽçŽ åã¯ã¡ãã«
ã§ããããã㊠R2ã¯ïœâãããã«ãïœâããã«ãã€ãœããã«
åã¯ã¿ãŒã·ã€ãªãŒâããã«ã§ãã ã®ïŒâïŒâïŒïŒâããããã·âïŒâã¢ã«ãã«ã¢ã
ãããããã·ïŒâïŒâããšãã«ïŒœâïŒâããšãã«â
ïŒâããããã³åã³ããã®é žä»å å¡©ã ïŒ ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«åŸããïŒâïŒâïŒïŒ
âããããã·âïŒâïœâãããã«ã¢ãããããã
ã·ïŒâïŒâããšãã«ïŒœâïŒâããšãã«âïŒâããã
ãã³âã¯ãããã€ãã¬ãŒãã ïŒ ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«åŸããïŒâïŒâïŒïŒ
âããããã·âïŒâïœâããã«ã¢ãããããã
ã·ïŒâïŒâããšãã«ïŒœâïŒâããšãã«âïŒâããã
ãã³âã¯ãããã€ãã¬ãŒãã ïŒ ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«åŸããïŒâïŒâïŒïŒ
âããããã·âïŒâïœâã¿ãŒã·ã€ãªãŒâããã«ã¢
ããããããã·ïŒâïŒâããšãã«ïŒœâïŒâããšãã«
âïŒâããããã³âã¯ãããã€ãã¬ãŒãã ïŒ ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«åŸããïŒâïŒâã¡
ãã«âïŒâïŒïŒâããããã·âïŒâïœâãããã«
ã¢ããâããããã·ïŒâïŒâããšãã«ïŒœâïŒâããš
ãã«âïŒâããããã³âã¯ãããã€ãã¬ãŒãã ïŒ ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«åŸããïŒâïŒâã¡
ãã«âïŒâïŒïŒâããããã·âïŒâïœâãããã«
ã¢ããâããããã·ïŒâïŒâããšãã«ïŒœâïŒâããš
ãã«âïŒâããããã³âã¯ãããã€ãã¬ãŒãã ïŒ ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«åŸããïŒâïŒïŒïŒ
âãžã¡ãã«âïŒâïŒïŒâããããã·âïŒâïœâã
ããã«ã¢ããâããããã·ïŒâïŒâããšãã«ïŒœâïŒ
âããšãã«âïŒâããããã³âã¯ãããã€ãã¬ãŒ
ãã ïŒ äžè¬åŒ åŒäžãåã³R1ã¯ç¬ç«ããŠæ°ŽçŽ åã¯ã¡ãã«
ã§ããããã㊠R2ã¯ïœâãããã«ãïœâããã«ãã€ãœããã«
åã¯ã¿ãŒã·ã€ãªãŒâããã«ã§ãã ã®ïŒâïŒâïŒïŒâããããã·âïŒâã¢ã«ãã«ã¢ã
ãããããã·ïŒâïŒâããšãã«ïŒœâïŒâããšãã«â
ïŒâããããã³åã³ãã®é žä»å å¡©ã補é ããæ¹æ³
ã«ãããŠã åŒäžãåã³R1ã¯åèšã®ãšããã§ãããã
ã㊠M6ã¯ã¢ã«ã«ãªéå±ã«ããªã³ã§ãã ã®ååç©ãåŒ ã®ãšãã¯ãããããªã³ãšåå¿ããããããŠãã®ã
ãã«ããŠåŸãããååç© ãåŒäžãåã³R1ã¯åèšã®ãšããã§ãã ãäžè¬åŒ R2âNH2 ïŒïŒ åŒäžãR2ã¯åèšã®ãšããã§ãã ã®ã¢ã«ãã«ã¢ãã³ãšåå¿ããããããŠåžæã«ãã
åŸãããåŒïŒïŒã®å¡©åºãé žä»å å¡©ã«è»¢åããã
ãšãç¹åŸŽãšããæ¹æ³ã ïŒ ååç©ïŒïŒãšååç©ïŒïŒã®åå¿ãäžæŽ»æ§
溶åªäžã§110ã140âã®éã®æž©åºŠã«ãããŠå®æœã
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒïŒ ååç©ïŒïŒãšååç©ïŒïŒã®åå¿ãéå°
éã®ãšãã¯ãããããªã³ïŒïŒãçšããŠ110ã140
âã®éã®æž©åºŠã«ãããŠå®æœãããç¹èš±è«æ±ã®ç¯å²
第ïŒé èšèŒã®æ¹æ³ã ïŒïŒ ååç©ïŒïŒãšååç©ïŒïŒã®åå¿ãäžæŽ»
æ§æº¶åªäžã§50ã100âã®éã®æž©åºŠã«ãããŠå®æœã
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒïŒ ååç©ïŒïŒãšååç©ïŒïŒã®åå¿ãéå°
éã®ã¢ãã³ïŒïŒã®äžã§50ã100âã®éã®æž©åºŠã«
ãããŠå®æœãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹
æ³ã ïŒïŒ æå¹éã®äžè¬åŒ åŒäžãåã³R1ã¯ç¬ç«ããŠæ°ŽçŽ åã¯ã¡ãã«
ã§ããããã㊠R2ã¯ïœâãããã«ãïœâããã«ãã€ãœããã«
åã¯ã¿ãŒã·ã€ãªãŒâããã«ã§ãã ã®ïŒâïŒâïŒïŒâããããã·âïŒâã¢ã«ãã«ã¢ã
ãããããã·ïŒâïŒâããšãã«ïŒœâïŒâããšãã«â
ïŒâããããã³åã³ãã®é žä»å å¡©ã補è¬åŠçã«èš±
容ã§ããæ äœåã¯åžéå€ãšå ±ã«å«æããããšãç¹
城ãšãããæäžæŽèè¬ã
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0581880A AT369739B (de) | 1980-11-28 | 1980-11-28 | Verfahren zur herstellung neuer 1-(3-(2-hydroxy-3alkylaminopropoxy)-2-thienyl)-3-phenyl-1- propanone und ihrer saeureadditionssalze |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS57118582A JPS57118582A (en) | 1982-07-23 |
JPH036149B2 true JPH036149B2 (ja) | 1991-01-29 |
Family
ID=3579917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56188511A Granted JPS57118582A (en) | 1980-11-28 | 1981-11-26 | Novel 1-(3-(2-hydroxy-3-alkylaminopropoxy)-2- thienyl)-3-phenyl-1-propanones, their salts and manufacture |
Country Status (9)
Country | Link |
---|---|
US (1) | US4352819A (ja) |
EP (1) | EP0053603B1 (ja) |
JP (1) | JPS57118582A (ja) |
AT (1) | AT369739B (ja) |
CA (1) | CA1176643A (ja) |
DE (1) | DE3169736D1 (ja) |
DK (1) | DK154216C (ja) |
FI (1) | FI72725C (ja) |
PT (1) | PT74051B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3316155A1 (de) * | 1983-05-03 | 1984-11-08 | Helopharm W. Petrik & Co Kg, 1000 Berlin | 2-(2'hydroxy-3'-(1,1-dimethylpropylamino)-propoxy)-1-thienylpropiophenon, seine saeureadditionssalze, verfahren zu seiner herstellung und arzneimittel |
JPS62178585A (ja) * | 1986-01-29 | 1987-08-05 | ã¬ããªâãµã³âã²ãŒã«ã·ã€ããããšã ã»ãâã»ãâ | ïŒâãïŒâïŒïŒâããããã·âïŒâã¢ã«ãã«ã¢ããããããã·ïŒâïŒâããšãã«ãâïŒâããšãã«âïŒâããããã³åã³ãããã®é žä»å 塩䞊ã³ã«ãããã®è£œé æ³åã³ããããå«ãè¬åŠççµæç© |
ES2036600T3 (es) * | 1986-10-29 | 1993-06-01 | Dieter Prof. Dr. Binder | Procedimiento para preparar 1-(3-(2-dialquilaminoetoxi)-2-tienil)-3-fenil-1-propanonas. |
AT392967B (de) * | 1989-01-24 | 1991-07-25 | Laevosan Gmbh & Co Kg | Neue 1-(3-(2-hydroxy-3-alkylaminopropoxy)-2- thienyl)-3-phenyl-1-propanone und verfahren zu deren herstellung |
DE3907512C2 (de) * | 1989-03-08 | 1997-08-14 | Laevosan Gmbh & Co Kg | Neue Aryloxy-alkylamine, deren Herstellung und diese enthaltende Arzneimittel |
FI90540C (fi) * | 1991-03-28 | 1994-02-25 | Neste Oy | MenetelmÀ 3-asemassa substituoidun tiofeenin valmistamiseksi |
JP4608372B2 (ja) | 2005-06-09 | 2011-01-12 | ãã€ãªãã¢æ ªåŒäŒç€Ÿ | ä¿æè£ çœ®ããã³ãã£ã¹ã¯è£ 眮 |
WO2016153094A1 (ko) * | 2015-03-26 | 2016-09-29 | ë¹ì€ë©ë¥Ž 죌ìíì¬ | 3-ììœììžìŽì€í ì ë첎ì ì ê·í ì ì¡°ë°©ë² |
CN106146455A (zh) * | 2015-03-30 | 2016-11-23 | 绎æ¯æŒæ ªåŒäŒç€Ÿ | 3-ç·æ°§åºå»å©è¡çç©åå ¶å¶å€æ¹æ³ |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2720613A1 (de) * | 1977-05-07 | 1978-11-16 | Basf Ag | Aminoderivate von substituierten hydroxy-thiophenen |
US4123550A (en) * | 1977-10-31 | 1978-10-31 | Syntex (U.S.A.) Inc. | Bicyclo[3.1.0]hexylethylaminocarbonyl-substituted heteroaryl cardiovascular agents |
-
1980
- 1980-11-28 AT AT0581880A patent/AT369739B/de not_active IP Right Cessation
-
1981
- 1981-11-17 DE DE8181890190T patent/DE3169736D1/de not_active Expired
- 1981-11-17 EP EP81890190A patent/EP0053603B1/de not_active Expired
- 1981-11-25 US US06/324,760 patent/US4352819A/en not_active Expired - Lifetime
- 1981-11-26 JP JP56188511A patent/JPS57118582A/ja active Granted
- 1981-11-26 FI FI813790A patent/FI72725C/fi not_active IP Right Cessation
- 1981-11-27 CA CA000391069A patent/CA1176643A/en not_active Expired
- 1981-11-27 PT PT74051A patent/PT74051B/pt not_active IP Right Cessation
- 1981-11-27 DK DK526981A patent/DK154216C/da not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE3169736D1 (en) | 1985-05-09 |
AT369739B (de) | 1983-01-25 |
ATA581880A (de) | 1982-06-15 |
DK526981A (da) | 1982-05-29 |
EP0053603B1 (de) | 1985-04-03 |
EP0053603A1 (de) | 1982-06-09 |
JPS57118582A (en) | 1982-07-23 |
FI72725B (fi) | 1987-03-31 |
FI813790L (fi) | 1982-05-29 |
DK154216B (da) | 1988-10-24 |
US4352819A (en) | 1982-10-05 |
PT74051A (en) | 1981-12-01 |
CA1176643A (en) | 1984-10-23 |
PT74051B (en) | 1983-04-26 |
FI72725C (fi) | 1987-07-10 |
DK154216C (da) | 1989-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0178874B1 (en) | Alkylsulfonamidophenylalkylamines | |
JP2637737B2 (ja) | æ°èŠãªè¬å€ | |
GB2054588A (en) | Amino-ether oxides and pharmaceutical formulations thereof | |
US3996214A (en) | 5-(1,1-Diphenyl-4-(cyclic amino) but-2-trans-en-1-yl)-2-alkyl-1,3,4-oxadiazoles and intermediates thereto | |
JPH036149B2 (ja) | ||
US3205136A (en) | Antidepressant phenyloxyalkylamines | |
US4029803A (en) | Method of treatment with 2-iminothiazolidines and thiazolines | |
US3109845A (en) | 1-cyclohexyl, 1-cyclohexenyl, 1-furyl, and 1-thienyl, tertiary amino substituted methanes | |
Leonard et al. | 2-thenyl substituted diamines with antihistaminic activity | |
US4034011A (en) | 1,1-Diphenyl-4-(substituted-amino)butanes | |
US3190893A (en) | Method of producing 9, 10-dihydroanthracenes | |
JPS628420B2 (ja) | ||
JPH0227355B2 (ja) | 88benzoiruaminoarukirupirorichijinjudotai | |
CA1298832C (en) | 3-phenyl-1-propanones, process of preparing thereof and method of treating arrhythmias | |
US4013667A (en) | 2,2-Diaryl-3-(1-azabicyclo[2.2.2]oct-2-yl)propionamides and intermediates thereto | |
JPS5935387B2 (ja) | ïŒâã¢ããâïŒâããããã·ãããã³ã®ãžâ眮æããšãâã«ãšâãã«é¡ããã®è£œæ³ãªãã³ã«å»è¬çšé | |
US3037982A (en) | Phenylpiperazinylalkyl propionanilides | |
US3969418A (en) | (4-Biphenylyl)-butenols | |
US3238242A (en) | Process for the preparation of phenyl (meta-and para-tolyl)-propionitriles | |
HU194213B (en) | Process for production of 3-alkoxi-2-n-pirrolidin-n-piridil-n-furil /or n-tienil/-methil-prophil amins | |
US4877809A (en) | Novel 2-thienyloxyacetic acid derivatives, a process for their preparation and pharmaceutical preparations containing them | |
US3799982A (en) | N-(beta,beta-difluoro,alpha-methylphenethyl)-formamide | |
US3907999A (en) | Substituted dibenzocyclooctene compositions | |
US3970656A (en) | 1-Alkyl-4-m-hydroxyphenyl-4-propionyl piperidines | |
JP2760998B2 (ja) | èèçŸæ£æ²»çå€ |